 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 January 1993 | Volume 118 Issue 2 | Pages 114-116
Fludarabine phosphate is approved for the treatment of advanced B-cell chronic lymphocytic leukemia refractory to alkylating agents. We report two cases of disabling but reversible neurotoxicity in a patient with mycosis fungoides and a patient with chronic lymphocytic leukemia who received standard doses of fludarabine [20 to 25 mg/m2 per day for 5 days] every 28 days for 6 to 8 cycles). Serial brain magnetic resonance imaging scans in the patient with mycosis fungoides showed rapid evolution of white-matter changes with subsequent complete resolution.
Author and Article Information
From the National Naval Medical Center and the National Cancer Institute, Bethesda, Maryland.
BRIEF REPORT
Reversible Neurologic Toxicity in Patients Treated with Standard-Dose Fludarabine Phosphate for Mycosis Fungoides and Chronic Lymphocytic Leukemia
Requests for Reprints: Roger B. Cohen, MD, NCI/Navy Medical Oncology Branch, National Naval Medical Center, Bethesda, MD 20889.
This article has been cited by other articles:
|
|
 |
|
  M. J. Cooney, W. G. Bradley, S. C. Symko, S. T. Patel, and P. K. Groncy Hypertensive Encephalopathy: Complication in Children Treated for Myeloproliferative Disorders-Report of Three Cases Radiology, March 1, 2000; 214(3): 711 - 716. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Hinchey, C. Chaves, B. Appignani, J. Breen, L. Pao, A. Wang, M. S. Pessin, C. Lamy, J.-L. Mas, and L. R. Caplan A Reversible Posterior Leukoencephalopathy Syndrome N. Engl. J. Med., February 22, 1996; 334(8): 494 - 500. [Abstract] [Full Text] [PDF]
|
|
Article
